Podcasts about wegovy

You've seen the ads. You've heard the buzz. But do you actually know what peptides are — or what they're doing inside your body? In this first episode of a three-part series, Jamie Preston sits down with Dr. Melissa Jones, a 25-year clinical pharmacist and VP at Your Health, to lay the foundation every patient and provider needs before entering the peptide conversation. Dr. Jones brings rare credibility to this space — she didn't come in as a believer, she came in as a scientist who was challenged to learn, and what she found changed how she practices. What you'll hear in this episode: Why insulin is a peptide — and why that means peptides have been in your medicine cabinet for years How BPC 157 and TB 500 work together to signal the body to heal — and the real patient stories behind that science Why GLP-1 medications like Mounjaro and Ozempic are peptides, and how they actually produce weight loss The difference between peptides and steroids (hint: one sends signals, one messes with your hormones) Why "research use only" labels are a red flag — and why compounding pharmacies matter more than you think What providers need to start asking patients right now Whether you're a patient who's been curious or a provider who's been hesitant, this episode gives you the grounded, evidence-informed starting point you've been looking for. Part two goes even deeper — but this is where it begins. www.YourHealth.Org

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show

Der er over 331.000 danskere, der ejer en Novo Nordisk aktie alene på Nordnet, viser handelsplatformens egne tal. Novo Nordisk er dermed suverænt den mest populære aktie og Danmarks eneste folkeaktie. Selskabet har været igennem en katastrofal nedtur de senere år og gået fra en aktiekurs på over 1.000 til omkring 323 kroner. Men er det endelig ved at lysne med en Wegovy-pille, der sælger langt bedre end forventet? Vi har inviteret analytiker Søren Løntoft Hansen med til at analysere Novo Nordisk grundigt i bund og stiller to grundlæggende spørgsmål: Vender skuden for Novo Nordisk, og hvis du skulle give ét råd til den almindelige danske Novo-investor, hvad ville det så være? I studiet: Magnus Barsøe og Søren Løntoft Hansen. See omnystudio.com/listener for privacy information.

It's our Summer Hiatus in between seasons 24 & 25. Join us as we present bonus tales from our Sleepless Universe for those hot summer nights."The Bothy" by Peter J Stewart (Story starts around 00:03:45)Produced by Phil MichalskiCast: Eric - David Ault, Mary - Ash Millman, Jack - Guy Woodward"The Aegis Group" by M Bohren (Story starts around 00:29:40)TRIGGER WARNING!Produced by Jesse CornettCast: Reid - Atticus Jackson, Dom - Dan Zappulla, Michael - Mike DelGaudio, John - Jeff Clement, Abe - Matthew Bradford, Lucian - Graham Rowat, Valkyrie - Kyle Akers, Bravo - Jesse Cornett, Hannah - Nichole GoodnightThis episode is sponsored by:Weight Loss by Hims - Ready to reach your weight loss goals? Weight Loss by Hims and WegovyÆ. Get a personalized, affordable plan that gets you. Go to Hims.com/nosleep.Indacloud - IndaCloud is a fully legal online cannabis dispensary for gummies, exotic flower, premium prerolls, Zero Sugar THC Sodas, Energy Gummies, and Extra Strength Sleep Gummies. If you're 21 or older, go to indacloud.co/nosleep to get 30% off your first order.Click here to learn more about The NoSleep Podcast teamCheck out our NEW MERCH!Executive Producer & Host: David CummingsMusical scores composed by: Brandon BooneSummer 2026 Hiatus 01 illustration courtesy of Alexandra CruzThe NoSleep Podcast is Human-made for Human Minds. No generative AI is used in any aspect of work.Audio program ©2026 - Creative Reason Media - The copyrights for each story are held by the respective authors. No duplication or reproduction of this audio program is permitted without the written consent of Creative Reason Media. No part of this audio program may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems. All rights reserved.

Apple's new Apple Upgrade leasing program offers lower monthly payments and easier upgrades for customers who frequently replace their devices. USA Today reports that doctors are increasingly seeing “temporal hollowing,” or sunken temples, among patients who have experienced rapid weight loss while using GLP-1 medications like Ozempic and Wegovy. Please Like, Comment and Follow 'Philip Teresi on KMJ' on all platforms: --- Philip Teresi on KMJ is available on the KMJNOW app, Apple Podcasts, Spotify, YouTube or wherever else you listen to podcasts. -- Philip Teresi on KMJ Weekdays 2-6 PM Pacific on News/Talk 580 AM & 105.9 FM KMJ | Website | Facebook | Instagram | X | Podcast | Amazon | - Everything KMJ KMJNOW App | Podcasts | Facebook | X | Instagram See omnystudio.com/listener for privacy information.

➢Apply for 1 on 1 coaching: https://colossusfitness.com/In this episode, we're breaking down some of the biggest viral fitness and health trends taking over TikTok and asking the big question: is it actually legit, or just hype?We dive into the 3-2-8 Method and whether combining strength training, Pilates, and daily steps is actually an effective approach. We also talk Hot Girl Walks, the explosion of HYROX and Half HYROX, and why hybrid training has become so popular.Then we tackle some of the more controversial trends, including GLP-1 medications like Ozempic and Wegovy, plus the rise of looksmaxxing and the obsession with optimizing your appearance.Some of these trends have real value. Others might be getting WAY more attention than they deserve.We're breaking down what's worth trying, what's overhyped, and what you can probably ignore.Thanks for listening! We genuinely appreciate every single one of you listening.➢Follow us on instagram @colossusfit➢Apply to get your Polished Physique: https://colossusfitness.com/

The Cutting Edge #26 Are you currently taking a GLP-1 medication (like Ozempic, Wegovy, Mounjaro, or Zepbound) and planning for plastic surgery or general anesthesia? In this critical episode of The Cutting Edge Podcast, host Mel sits down with bariatric therapist Ashlyn Douglass-Barnes and board-certified plastic surgeon Dr. Omar Beidas to unpack the medical, psychological, and surgical risks every patient must know. If you are navigating weight loss surgery, post-bariatric skin removal, or GLP-1 therapy, this video explains why stopping your injection before surgery isn't optional—it could literally save your life.

Sure, there are weight-loss success stories, but behind the scenes people are navigating insurance challenges, side effects, and the possibility of taking GLP-1 medications for life. For some people, they've been life-changing. For others, they are rethinking whether the drug is worth it. In the Loop talks with a panel of residents across the Chicago region about how these medications changed their health, their relationship with food, and the complicated decisions involved in taking or stopping GLP-1 drugs.GUESTS: Linda Nemec, Sleepy Hollow, Ill., residentDr. Ahsan Basha, oncologist, Edgewater residentBetsy Elsaesser, Logan Square residentFor a full archive of In the Loop interviews, head over to wbez.org/intheloop.

In this replay episode, we interview obesity medicine specialist Dr. Alexandra Sowa, author of The Ozempic Revolution. The discussion demystifies GLP-1 medications such as Ozempic, Wegovy, semaglutide, and tirzepatide, explaining how they work, who they are designed for, and why they represent a major shift in the treatment of obesity and metabolic disease. Dr. Sowa emphasizes that obesity is not a failure of willpower, but a complex chronic disease driven by genetics, hormones, metabolism, and environmental factors.  Our discussion moves beyond the basics of GLP-1 medications like Ozempic, Wegovy, Zepbound, and semaglutide to explore practical questions many patients have: *How much do these medications cost? * Will insurance cover them? * What are the side effects? * How long do you need to stay on treatment? * And what lifestyle changes are essential for lasting success? Dr. Sowa explains that GLP-1 medications are powerful tool, but they are not a magic solution. Sustainable weight loss and improved metabolic health require proper nutrition, strength training, medical supervision, and a long-term commitment to healthy habits. Show Notes/Links: www.hotflashescooltopics.com JOIN THE HOT FLASHES & COOL TOPICS PODCAST COMMUNITY: Website: www.hotflashescooltopics.com Newsletter: Link Mail:  hotflashescooltopics@gmail.com Instagram https://www.instagram.com/hotflashesandcooltopics Facebook : www.facebook.com/hotflashescooltopics YouTube https://www.youtube.com/@HotFlashesCoolTopics  

Los fármacos análogos de GLP-1 (Ozempic, Wegovy, Mounjaro...) están revolucionando el tratamiento de la obesidad y el sobrepeso, pero hay una dimensión de la que se habla muy poco: el ruido mental (food noise) y el estigma social.En este episodio analizamos:¿Qué es el ruido mental alrededor de la comida? Cómo los pensamientos intrusivos constantes afectan a la relación con la alimentación y por qué el GLP-1 apaga ese "ruido".El juicio de la sociedad: Por qué se acusa injustamente de "hacer trampa" o de "falta de voluntad" a quienes recurren al tratamiento farmacológico.El abordaje integral: Por qué la medicación no es una varita mágica y necesita ir acompañada de reeducación nutricional, ejercicio de fuerza y apoyo psicológico para ser sostenible.Un episodio necesario para romper prejuicios y entender la obesidad desde la ciencia, la empatía y la salud.Conviértete en un supporter de este podcast: https://www.spreaker.com/podcast/comiendo-con-maria-nutricion--2497272/support.

Everyone's talking about Ozempic. But almost no one tells you what it's quietly doing to your body, or how to use it without paying for it later.Justin Roethlingshoefer breaks down the long-term side effects of GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound (semaglutide and tirzepatide): the muscle and bone you lose, why people quit, what happens when you stop, and the protocol to do it right.This episode isn't anti-GLP-1. For type 2 diabetes, severe obesity, or high cardiovascular risk these drugs can be extraordinary. But in the STEP 1 trial, 40% of the weight lost was lean body mass: for every 10 pounds gone, up to 4 can be muscle.In this episode:

Traveling while taking Ozempic, Wegovy, Mounjaro, or Zepbound? Wondering how to enjoy your vacation without feeling like you're undoing all of your progress?The good news is—you don't have to choose between making memories and staying on track.In this episode, Registered Dietitian, Certified Personal Trainer, Gianna shares her practical, flexible approach to traveling on a GLP-1. From airports and road trips to cruises, all-inclusive resorts, and family vacations, you'll learn how to confidently navigate food, movement, hydration, and your medication—without guilt or perfectionism.Because the goal isn't to have the "perfect" vacation. The goal is to enjoy your trip, take care of yourself, and come home ready to jump back into your routine.In this episode, you'll learn:How to prepare for travel while taking a GLP-1Tips for flying with Ozempic, Wegovy, Mounjaro, or ZepboundEasy, protein-rich travel snacks to packHow to eat at buffets, restaurants, and on vacation without overthinking itWhy movement doesn't have to look like a gym workout while travelingWhat to do if the scale is higher after vacationHow to get back into your routine without guilt, detoxes, or "starting over"Why flexibility is one of the most important skills for long-term successIf you've ever worried about gaining weight on vacation or wondered how to travel while taking a GLP-1 medication, this episode is full of practical strategies you can use on your very next trip.

(00:00): Hvorfor er det så vigtigt at kunne bade og sole nøgen i offentligheden? Medvirkende: Lisbeth Dam Larsen, Tidligere medlem af kommunalbestyrelsen i Dragør for Moderaterne og bruger af Dragør Søbad. (42:00): Bliver børn og unge med spiseforstyrrelser fejlbehandlet med Wegovy? Medvirkende: Camilla Hersom, Direktør i Somenta. Værter: Peter Marstal og Nicolai DandanellSee omnystudio.com/listener for privacy information.

¿Has escuchado maravillas sobre medicamentos como Ozempic, Wegovy o Mounjaro, pero nadie te habla de las constantes náuseas y el malestar estomacal? La realidad clínica es que una gran parte de los pacientes abandonan estos tratamientos para la obesidad simplemente porque los efectos secundarios arruinan su calidad de vida. Pero la ciencia médica está a punto de dar un salto monumental. En este episodio, descubriremos a la AMILINA, una hormona producida por tu páncreas que está demostrando resultados asombrosos en ensayos clínicos: pérdida de peso significativa sin los severos vómitos ni malestares intestinales de los fármacos actuales. En este episodio aprenderás: → Cómo tu páncreas libera dos hormonas cada vez que comes. → Cómo la amilina bloquea el freno metabólico que hace que recuperes el peso perdido. → Cómo dos equipos de investigadores resolvieron el mismo problema químico de formas distintas. → Cómo la combinación CagriSema alcanza una reducción significativa del peso corporal. → Por qué la amilina resensibiliza tu cerebro a la leptina, algo que la semaglutida no logra.   Mi nombre es Dr. Mauricio González, médico internista y especialista en endocrinología en formación. Aquí comparto información basada en evidencia para que tomes decisiones de salud sin mitos ni marketing engañoso. Suscríbete a mi boletín informativo en: www.drmauriciogonzalez.com/   ⚠️ Este podcast tiene fines exclusivamente educativos e informativos y no constituye asesoramiento médico, diagnóstico ni tratamiento personalizado. Los medicamentos que se discuten en este episodio se encuentran en fase de investigación y no cuentan con aprobación de la FDA. Consulta siempre a tu médico o a un profesional de la salud calificado antes de cambiar tu régimen de tratamiento.   ¡Sigamos la conversación en redes sociales! Instagram

The Ukrainian President Volodymyr Zelensky has fired his army commander-in-chief, Oleksandr Syrskyi, in one of the biggest shake-ups of the country's military leadership since the start of Russia's full-scale invasion. General Syrskyi had clashed with the popular defence minister, Mykhailo Fedorov, whose own removal from office last week triggered rare mass protests in Ukraine. Also: France becomes the first country in the EU to ban children under the age of 15 from using social media. A special report from the school in Iran where 156 people, mostly children, were killed at the start of the US-Israeli war. As Venezuela's ousted leader Nicolás Maduro is due back in court in New York, Venezuelans tell the BBC they are too focused on trying to rebuild their lives after the earthquakes to give much thought to the criminal proceedings. The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action against its rival Eli Lilly, accusing it of false advertising in suggesting its weight-loss drugs perform better. Animal welfare experts in Britain are looking after a marmoset monkey that was found abandoned in a laundry bag on a London bus. And we look at the new developments in sleep health technology focusing on disease prediction.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.ukPhoto: Ukraine's President Zelensky and now former Commander in Chief of the Ukrainian Armed Forces, Colonel General Oleksandr Syrskyi, visit an exhibition of new Ukrainian made drone-missiles Peklo in Kyiv. Credit: REUTERS/Valentyn Ogirenko

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode, we break down Novo Nordisk's lawsuit accusing Eli Lilly of misleading patients through advertisements comparing Zepbound and Mounjaro with Wegovy and Ozempic. The fight is not simply about which medication produces more weight loss. It is about who controls the information patients receive, which evidence gets highlighted, and what gets left in the fine print.Then we examine STAT News' investigation into LifeMD, a major telehealth company promoted by Novo as a legitimate pathway to GLP-1 treatment. Former employees alleged providers were pushed to process patients at breakneck speed, sometimes reviewing as many as 25 cases per hour, while refill queues, dose increases and patient messages piled up. LifeMD strongly disputes those allegations.But this cannot become another simplistic story about telehealth being bad.More than 100 million Americans are living with obesity, and only a small number of clinicians have dedicated obesity medicine expertise. The traditional healthcare system does not have enough specialists, appointment slots or geographic reach to provide every patient with an ideal, hour-long consultation.So how altruistic can we afford to be about access?Can we demand a perfect standard of care that most patients will never be able to reach? Or does scaling treatment too aggressively risk turning patients into transactions inside a prescription machine?Access cannot become a shield for negligence. But perfection cannot become another form of gatekeeping.The patient is being fought over. This episode asks what it would actually mean to fight for them.Learn more and follow On The Pen: https://www.otplinks.comThis episode is sponsored by VoaFit, where I receive care for obesity and metabolic health. https://www.voafit.com/otp to learn more!

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Behind closed doors, Sloane saw what most people never will.  Working secretly for an escort agency, she came face-to-face with the rawest, darkest sides of humanity. Now, she's pulling back the curtain, revealing her journey from sugar baby, to dancer, to escort. It's an unfiltered look into an industry often misunderstood, and rarely revealed so honestly.  HERS Thank you, HERS!  forhers.com/SECRET for your personalized, affordable care that gets you. Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A/S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit forhers.com. HOMECHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life!  HomeChef.com/SECRET.  Must be an active subscriber to receive free dessert. MINT MOBILE Make the switch! MINTMOBILE.com/SECRET PICTURES See a picture of Sloane now on Threads, Facebook, Instagram and X.  Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Susanna's mom was always deeply religious, and followed her own path to discover her connection to a higher power. When Susanna was in high school, her mom met a calm and kind man.  Who was Susanna to think her mom wasn't completely certain he was the real deal? Her new step dad and her mom were both convinced he was actually Jesus reincarnated, and that it was just a waiting game of when to tell the world he was back. And so the journey began with her new dad, Jesus, with skin on.Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See this week's sponsors and their offers at secretroompodcast.com/codes  FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page!  Just ask to join, all are welcome. :) YOUR SECRET  Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!  

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

I'm explaining why feeling "lazy" has nothing to do with willpower and everything to do with your metabolism, hormones, stress, and the survival mechanisms built into your body. Learn how insulin, cortisol, visceral belly fat, metabolic flexibility, and healthy habits work together to help you lose weight naturally, without guilt, shame, or punishing yourself.GET A CUSTOMIZED WEIGHT LOSS PLAN:Have a free 1-on-1 call with our Expert Nutritionists

Novo Nordisk Group General Counsel & Senior Vice President John Kuckelman speaks with Bloomberg's Dani Burger and Isabelle Lee after the company on Tuesday accused rival Eli Lilly of misleading advertising. Novo says that Lilly’s advertising campaigns rely on outdated weight-loss comparisons with lower doses of Novo’s own obesity shot Wegovy than what’s currently available, according to the complaint.See omnystudio.com/listener for privacy information.

As current understandings of obesity (ie, a chronic disease requiring long-term management) are adopted across the world, screening and treatment can no longer follow a one-size-fits-all approach. Listen in as 3 global experts in obesity medicine highlight the emerging evidence from recent conferences that are changing real-world practice today. Learn how the latest findings apply to specific patient populations across the United States, Europe, and Asia as well as why healthcare professionals should individualize treatment based on patient preferences and relevant risk factors. Presenters: Stephano Del Prato, MD Professor Emeritus of Endocrinology University of Pisa Pisa, Italy Soo Lim, MD, PhD Professor of Medicine Department of Internal Medicine Seoul National University College of Medicine and Seoul National University Bundang Hospital Seoul, South Korea Donna H. Ryan, MD Professor Emerita Pennington Biomedical Research Center Louisiana State University New Orleans, Louisiana Link to full program:https://bit.ly/4pwFhEo Get access to all of our new podcasts by subscribing to the Decera Clinical Education Multispecialty Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Jamie Dimon gaat Warren Buffett achterna. Ook hij vindt dat er geen goede aankopen meer te vinden zijn op de beurs. Al jaren dramt Dimon bij elke cijferpublicatie van zijn bank dat er een lange lijst aan risico's boven de markt hangt. Geopolitieke spanningen, instabiele inflatie, expoloderende staatsschulden: de kans is groot dat ze niet voldoende worden ingeprijst, denkt Dimon. Moet jij hem daarin volgen? Dat hoor je in deze aflevering. We hebben het ook over Samsung. Die maken al chips, koelkasten, televisies, telefoons, en nog veel meer. Maar het is allemaal niet genoeg. Ze gaan nu ook aan de humanoïde robots. Er wordt een aparte divisie voor opgezet, onder leiding van een van de co-CEO's zelf. Gaan ze de concurrentiestrijd met bijvoorbeeld Tesla winnen? Verder hoor je ook over een poging van de Londense beurs om weer aandacht te krijgen. Daarom gaan ze de openingstijden flink verbreden. Ze willen eigenlijk handel 24 uur per dag mogelijk maken. En we vertellen je hoe de strijd tussen farmaceuten Novo Nordisk en Eli Lilly nu naar de rechtszaal wordt verplaatst. Te gast: Thomas Pellegrom, van ABN Amro MeesPierson BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

Can you still eat at restaurants while taking Ozempic, Wegovy, Mounjaro, or Zepbound?Absolutely.One of the biggest misconceptions about GLP-1 medications is that you have to avoid restaurants, skip vacations, or order the “healthiest” item on the menu to lose weight. The truth? Long-term success comes from learning how to navigate real life—not avoiding it.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna Beasley shares her simple, evidence-based strategy for eating out while staying true to your health goals. You'll learn how to build balanced meals, listen to your body's fullness cues, and enjoy restaurant meals without guilt, stress, or overthinking every bite.Whether you're headed to date night, a family dinner, a work lunch, or vacation, this episode will help you feel confident ordering at almost any restaurant while taking a GLP-1.In this episode, you'll learn:How to order at restaurants while taking a GLP-1A simple meal-building formula you can use almost anywhereWhy you don't need to avoid eating out to be successfulHow to prioritize protein without obsessing over caloriesWhat to do when you feel full halfway through your mealTips for reducing nausea or digestive discomfort when dining outHow to navigate appetizers, desserts, and drinks without guiltWhat to say when people comment on how much—or how little—you're eatingIf you've ever searched “What should I order on Ozempic?”, “Can I eat at restaurants on Wegovy?”, or “How do I eat out on a GLP-1?”, this episode is for you.

Have you heard of Farxiga (dapagliflozin), Jardiance (empagliflozin), Ozempic, Wegovy, Mounjaro, or finerenone, but aren't quite sure what they do or whether they're right for people living with kidney disease?   In this episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Professor Alex, Consultant Nephrologist and researcher, for an essential conversation about some of the biggest breakthroughs in kidney medicine in recent years.   Originally developed for diabetes, SGLT2 inhibitors have transformed kidney care and are now helping to protect kidney function, reduce protein in the urine and improve outcomes for many people living with chronic kidney disease (CKD). We also explore the growing role of GLP-1 receptor agonists and finerenone, and explain what patients need to know about these treatments.   Whether you're living with chronic kidney disease, caring for someone who is, or you're a healthcare professional wanting a patient-friendly explanation, this episode is packed with practical, evidence-based information.   In this episode, you'll learn:   ✅ What SGLT2 inhibitors are and how they protect the kidneys ✅ Why medications developed for diabetes are now transforming kidney care ✅ How GLP-1 receptor agonists (including Ozempic, Wegovy and Mounjaro) may benefit kidney health ✅ What finerenone is and who may benefit from it ✅ Why your eGFR may temporarily fall after starting treatment—and why this isn't always a cause for concern ✅ The benefits and possible side effects of these medications ✅ Which kidney patients may be suitable for these treatments ✅ The latest developments in kidney research and future treatments   This episode shares expert insight designed to educate, empower and inspire people living with kidney disease and those who support them.  

A New Zealand clinical study's found plant-based weight loss alternatives can stimulate the same hormones targeted by the likes of Ozempic and Wegovy. Calocurb researchers say participants lost an average of nearly four kilos over six months, compared with less than half a kilo for those taking a placebo. The natural GLP-1 activator is made from Kiwi hops and vegetable oil and is designed to preserve lean muscle. Calocurb CEO Sarah Kennedy told Mike Hosking it's changed the conversation around weight loss. She says it stimulates a natural hormone to make people eat less. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Did you know that your body already makes its own natural version of Ozempic?In this episode, you'll hear how GLP-1 works as a natural hormone, and why drugs like Ozempic and Wegovy exist: they copy the same hormone but are designed to last much longer.You'll hear how the GLP-1 that naturally disappears from your body in two minutes got turned into an appetite-reducing drug that lasts a full week.You'll also hear about what happens to people's weight after they stop taking GLP-1 drugs, as well as what leptin resistance actually is, and whether cutting sugar can reverse it better than GLP-1 drugs. Are GLP-1 drugs for you? Or does cutting sugar give the same result?And are you ready to go deeper and ask yourself why you turn to sugar to fill an emotional need?Only you have the answer! (But I will give you a few...)To get personalized guidance to stop emotional eating and break free from sugar cravings, plus support and accountability... join the 90-day program, Freedom from Cravings Formula TODAY.For step-by-step guidance toward freedom from cravings, get your copy of my new book: "Break Free from Sugar Cravings". Available on Amazon now!For free resources, Do the Cravings Quiz and take the first step to get rid of your cravings! Download your 5 tips HERE to discover how you can get rid of cravings... even when you feel tired or stressed.To rate and review this podcast:scroll down in your podcast player on your phone and click on the stars. To leave a review, scroll down a little more and click on "Write a Review". Once you've finished, select “Send” or “Save” in the top-right corner. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed on your review.After selecting a nickname, tap OK. Your review may not be immediately visible, but it should be posted soon. Thank you! - NettaDisclaimer: Information provided by Life After Sugar is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. This is general information for educational purposes only. The information provided ...

L'internet adore les explications simples sur l'obésité. Mangez moins, bougez plus, faites preuve de volonté. Dans cet épisode, un chirurgien bariatrique et une psychologue clinicienne expliquent pourquoi cette vision ne tient pas compte de la réalité humaine ni de la biologie. Si vous vous êtes déjà senti jugé en raison de votre poids, ou si vous vous êtes déjà reproché d'avoir repris du poids, cette conversation remplace la culpabilité par la science.Nous abordons l'obésité comme une maladie chronique influencée par la génétique, les hormones, le métabolisme, les médicaments, le stress, les mécanismes d'adaptation et un environnement rempli d'aliments peu coûteux et hyperappétents. Vous découvrirez que les interventions comme la gastrectomie en manchon et le pontage gastrique font bien plus que réduire la taille de l'estomac. Elles modifient aussi les hormones de la faim et de la satiété, notamment la ghréline et le GLP, tout en permettant de mieux comprendre des concepts comme la théorie du point d'équilibre pondéral, ainsi que les raisons pour lesquelles le corps résiste souvent à une perte de poids durable.Nous discutons également des aspects psychologiques de l'obésité, notamment l'alimentation émotionnelle, le bruit alimentaire, la stigmatisation liée au poids, les changements d'identité après la chirurgie et les raisons pour lesquelles mesurer le succès uniquement avec le chiffre sur la balance peut devenir contre-productif. Vous découvrirez aussi des stratégies concrètes, comme prioriser les protéines et les fibres pour favoriser la satiété et réduire la faim, ainsi que des approches réalistes pour bâtir des habitudes durables.Enfin, nous parlons des médicaments agonistes du GLP, 1, comme Wegovy, Ozempic, Mounjaro et Zepbound. Nous expliquons leur rôle dans le traitement de l'obésité, pourquoi ils sont souvent mal compris et pourquoi les meilleurs résultats sont obtenus lorsqu'ils sont combinés à des changements durables des habitudes de vie et à un suivi régulier.Si cette conversation vous a été utile, abonnez-vous, laissez un avis et partagez cet épisode avec une personne qui pourrait bénéficier d'une vision plus compatissante et fondée sur les données scientifiques de l'obésité.Go check out my website for tons of free resources on how to transition towards a healthier diet and lifestyle.You can download my free plant-based recipes eBook and a ton of other free resources by visiting  the Digital Downloads tab of my website at https://www.plantbaseddrjules.com/shopDon't forget to check out my blog at https://www.plantbaseddrjules.com/blog You can also watch my educational videos on YouTube at https://www.youtube.com/channel/UCMpkQRXb7G-StAotV0dmahQCheck out my upcoming live events and free eCourse, where you'll learn more about how to create delicious plant-based recipes: https://www.plantbaseddrjules.com/Go follow me on social media by visiting my Facebook page and Instagram accountshttps://www.facebook.com/plantbaseddrjuleshttps://www.instagram.com/plantbased_dr_jules/Last but not least, the best way to show your support and to help me spread my message is to subscribe to my podcast and to leave a 5 star review on Apple and Spotify!Thanks so much!Peace, love, plants!Dr. Jules 

From Apple News In Conversation: GLP-1 drugs like Ozempic and Wegovy are being taken by millions of Americans. These medications have been approved for treating diabetes, obesity, and a small number of other chronic conditions. But even as experts are still learning how the drugs work, many people have found that they help with other disorders — from addiction to brain fog to arthritis — where anecdotal evidence is promising but the formal research hasn’t caught up. Julia Belluz, a contributing writer for the New York Times Opinion section and coauthor of Food Intelligence, joins Apple News In Conversation guest host David Greene to explain why what’s unfolding right now may be the largest uncontrolled drug experiment in modern history.

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

Ozempic is helping millions lose weight—but what if it's also causing a hidden form of muscle loss most people never see coming?"Ozempic feet" has become a viral term, but the real concern isn't just how your feet look—it's what rapid weight loss may be doing to your muscle mass, strength, metabolism, and long-term health.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the truth behind Ozempic muscle loss, why it happens, who is most at risk, and the science-backed strategies to rebuild lean muscle while protecting your health.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication—or considering one—this is information you need before your next step.Supplements Featured In This Episode:• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast®  https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz Not sure what food to eat and avoid? This guide is for you.⬇️

In this series, Going Deep, we’ll be doing bite-sized explorations into the most interesting industries, businesses and economic events… in Australia and around the world. For today's episode, we're diving into the weight loss drug economy - a $58 billion industry built on injections that hack your hunger signal. We've seen food companies scramble to reformulate their products, airlines calculate what lighter passengers mean for their fuel bill and gyms completely rewrite their pitch. In this episode, we'll explore how Ozempic and Wegovy went from diabetes treatments to cultural phenomena…and what a world of meaningfully lighter people actually means for business, public health, and your hip pocket. _ Note: This recording took place in February 2026. All numbers noted were accurate as of this date. Want to lean how to go from a Saver to Investor in just 7 days - watch our new series here Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay Daily newsletter: https://bit.ly/fluxnewsletter Flux on Instagram: http://bit.ly/fluxinsta Flux on TikTok: https://www.tiktok.com/@flux.finance —- The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes. ____See omnystudio.com/listener for privacy information.

Few prescription drugs have generated as much excitement as the new generation of weight-loss drugs, commonly called “GLP-1” medications. You've probably heard about Ozempic, Wegovy, Zepbound, and Mounjaro, even if you don't want to lose weight.In this episode: How do these drugs work? How to deal with the sometimes-unpleasant side effects? What has the GLP-1 family of drugs been proven to do, and what could they be used for in the future? Plus, details about a new Medicare program that now covers these drugs when prescribed for weight loss for those who qualify.Not a Checkbook member? ⁠⁠⁠⁠⁠⁠Sign up for a free 30-day trial to access all of our unbiased ratings⁠⁠⁠⁠⁠⁠.

GLP-1 drugs like Ozempic and Wegovy are being taken by millions of Americans. These medications have been approved for treating diabetes, obesity, and a small number of other chronic conditions. But even as experts are still learning how the drugs work, many people have found that they help with other disorders — from addiction to brain fog to arthritis — where anecdotal evidence is promising but the formal research hasn’t caught up. Julia Belluz, a contributing writer for the New York Times Opinion section and coauthor of Food Intelligence, joins Apple News In Conversation guest host David Greene to explain why what’s unfolding right now may be the largest uncontrolled drug experiment in modern history.

Vivian dives into the "thinness economy" and the surprising ways weight bias can affect your finances, career, and earning potential. From GLP-1 medications like Ozempic and Wegovy to workplace discrimination, social media beauty standards, and the booming weight loss industry, this episode explores the uncomfortable intersection of money, health, and appearance. In this episode, you'll learn: 1. How weight bias impacts hiring, salaries, promotions, and long-term wealth, why obesity is a disease rather than a moral failure, and the hidden economic costs of discrimination. 2. The real financial tradeoffs of GLP-1 medications, including who can actually afford them, what insurance does and doesn't cover, and whether these drugs are a financial investment or simply another expensive response to societal pressure. 3. How the "thinness economy" is reshaping entire industries… from grocery stores and restaurants to airlines, fashion, and healthcare, and what these shifts mean for your wallet and the future of consumer spending. Follow the podcast on Instagram and TikTok! Got a financial question you want answered in a future episode? Email us at podcast@yourrichbff.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Weight-loss drugs like Ozempic and Wegovy are one of the fastest growing pharmaceuticals. But as newer GLP-1 medications hit the market, questions remain about side effects, health equity and the cultural impact. On today's In the Loop, we ask: what have we learned so far about the popular drug? And how have GLP-1s changed the way we think about health and weight loss?GUESTS: Dr. Micah Eimer, cardiologist, clinical assistant professor of medicine in the division of cardiology at Northwestern University Feinberg SchoolDavid D. Kim, PhD, assistant professor of medicine and public health sciences at University of ChicagoRachelle Lacroix Mallick, registered dietician and nutritionist with a focus on reproductive healthFor a full archive of In the Loop interviews, head over to wbez.org/intheloop.

Free Ozempic?! Eat Your Way to the GLP-1 Effect + Why Women Are Hungry with guest expert Dominique Ludwig - #66Want Ozempic Fx without the Rx?What if the answer to better energy, fewer cravings, improved hormones, and sustainable weight management isn't another diet… but relearning how to eat?This week Samantha sits down with leading clinical nutritionist and No Nonsense Nutrition author Dominique Ludwig to unpack what really drives hunger, “food noise,” cravings, blood sugar swings, and the changes women experience through midlife and menopause. Together they break down the science behind naturally supporting satiety hormones like GLP-1, why calorie counting may not be the answer, and how simple shifts can completely change your relationship with food.This conversation is practical, evidence-informed, and refreshingly free of extremes.In this episode you'll learn:Discover the real biological reason cravings, fatigue, and midsection weight gain might not be a willpower issue at allFind out how to naturally activate the same hormone behind Ozempic and Wegovy — using your dinner plateLearn the Triple 30 Method and why these three specific numbers matter more than ever in midlifeUncover why calorie counting misses the point — and what to focus on insteadHear the honest truth about who GLP-1 medications are (and aren't) right forGet the science behind why a handful of nuts may not "cost" you as many calories as you thinkUnderstand the surprising gut-to-hormone pathway that connects fiber to estrogen balanceLearn what actually happens in your body during the "invisible" metabolic shift after 40Discover the real difference between mindful snacking and "grazing" — and why it mattersFind out how to judge protein powder, fermented foods, and resistant starch without the overwhelmAbout Our Guest:Dominique Ludwig is one of the UK's leading nutritionists, with an MSc in Nutrition from King's College London and over 30 years of clinical experience supporting more than 4,500 people worldwide.A Registered Nutritional Therapy Practitioner and Fellow of the British Association of Nutrition and Lifestyle Medicine, she is the author of the instant #1 Sunday Times bestseller No-Nonsense Nutrition, and the founder of the Renew Reset Recharge® and Triple 30 programs. Her work has been featured in The Sunday Times, The Telegraph, and SheerLuxe.

Send us Fan MailFREE — SEE WHERE YOUR PRACTICE IS BLEEDING REVENUE IN 3 MINUTES Take the RECOVER Diagnostic Quiz: https://eligibility.natrevmd.com/recover-quiz-lp More free resources: https://natrevmd.com/trusted-resources/ Payment Posting Audit Checklist: https://eligibility.natrevmd.com/payment-posting-checklistWE ARE RE-AIRING THIS EPISODE BECAUSE IT MATTERS RIGHT NOW. On July 1, 2026, the Medicare GLP-1 Bridge went live. Every independent practice with Medicare patients on Wegovy, Zepbound KwikPen, or Foundayo for weight management is now facing retrospective prior authorizations routed through a central processor most billing teams have never worked with. The AMA released physician guidance on June 26. The workflow is new. The documentation burden is heavier than most practices have modeled. And prior auth was already the fastest-growing revenue threat independent practices face. In this episode Dr. Heather walks through: WHAT WE COVER Why prior auth denials are silently eating clinical time and revenue The dollar amount your practice is losing every month (and how to calculate it) The 5-step workflow to manage prior auth without drowning your team What every practice needs to change this week "Prior auth has a dollar amount attached to it. Most practices never calculate it." THREE ACTIONS THIS WEEK 1. Calculate what prior auth is costing your practice in staff hours, denied claims, and clinical time 2. Set up a central prior auth tracker (do not run this out of email threads) 3. Train the team on the Medicare GLP-1 Bridge central processor workflow before the backlog compounds

Recent studies say that somewhere between 12 and 16 percent of Americans have used GLP-1s like Ozempic, Wegovy, or Zepbound. Many people who take these drugs report that the meds have fundamentally changed their relationship to food. Jason Diamond is a writer who covers food, men's fashion, and culture. Throughout his life he's had a complicated relationship with both food and medication, which played a big role in how he thought about whether or not, as a new dad, to start taking GLP-1s.  Jason's story in New York Magazine is “Eating With My Daughter and My Zepbound.” The Sporkful production team includes Dan Pashman, Emma Morgenstern, Andres O'Hara, Kameel Stanley, and Jared O'Connell. Right now, Sporkful listeners can get three months free of the SiriusXM app by going to siriusxm.com/sporkful. Get all your favorite podcasts, more than 200 ad-free music channels curated by genre and era, and live sports coverage with the SiriusXM app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

(00:00:00) 224: DOCs Itchy&Bitchy Answer YOUR Questions - Global Edition! (00:00:11) Welcome to Itchy and Bitchy (00:00:42) Doc Itchy Medical Pets Supplements (00:02:32) Hormone Replacement and GLP-1: Navigating Medical Decisions (00:08:06) Brain Fog and Alzheimer's: When to Worry (00:11:11) Menopause in Dogs: A Misunderstanding (00:16:48) The Truth About Alcohol Consumption (00:22:10) GLP-1 and Addiction: A Complex Discussion (00:27:41) Probiotics: The Unknown Frontier (00:32:05) Closing Thoughts on Supplements and Health Ask Docs Itchy&Bitchy:Your Questions on Weight, Hormones, and the GLP-1 additction ...You're writing in from everywhere, and your questions don't hold back, so neither will we. Why is your dog carrying extra weight even though nothing about mealtime has changed? On the human side: does Ozempic actually rewire your brain's reward system, not just your appetite? Emerging research says GLP-1 drugs quiet the same dopamine pathway that drives cravings for food, alcohol, and drugs which raises a wild question we're tackling this season: could a diabetes drug end up treating addiction? We're also digging into whether "Ozempic personality changes" are real, why weight-loss drugs hit women differently at midlife, and what nobody's telling you about pet supplements.Got a question? Send it — nothing's off limits.Visit itchyandbitchy.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/itchy-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system.  From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too.  For chronic illness warriors, self-advocacy seekers: WE OFFER  No BS 

Has your weight loss suddenly stopped on Ozempic, Wegovy, Mounjaro, or Zepbound?If the scale hasn't moved in weeks and you're wondering whether your GLP-1 has stopped working, you're not alone. Weight loss plateaus are one of the most common—and frustrating—parts of the GLP-1 journey.The good news? A plateau doesn't automatically mean you've done something wrong or that your medication has failed.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 expert Gianna explains why weight loss plateaus happen, what your body is actually doing, and the evidence-based questions she asks clients before making any changes.We'll cover:What actually counts as a weight loss plateauWhy weight loss naturally slows over timeThe difference between normal weight fluctuations and a true stallCommon reasons GLP-1 weight loss plateaus happenHow protein, hydration, fiber, sleep, stress, and movement influence progressWhy eating less isn't always the answerWhen it may be time to talk with your healthcare providerThe mindset shift that helps you move through a plateau without panicIf you've been asking yourself, “Why did my weight loss stop on Ozempic?” or “Why isn't my GLP-1 working anymore?” this episode will help you understand what may be happening and what to focus on next.

Today we're tackling one of the hottest topics in medicine, nutrition, and weight loss. GLP-1 medications.You know them by names like Ozempic, Wegovy, Mounjaro, and Zepbound. You've seen the commercials.You've heard the celebrity stories. You probably know someone taking one. Maybe you're taking one yourself.These medications have transformed the conversation around weight loss, and for many people they have been life-changing. But they've also raised some important questions. Can we naturally stimulate our own GLP-1? And now, Can fasting provide some of the same benefits?And is the future of weight management medication, lifestyle, or a combination of both? Fasting & GLP-1

Coming up, Wegovy weight loss pills are now available in pharmacies and online in the UK. Will they help tackle obesity? Plus, how scientists are trying to restore sensation in the feet; the legacy of Dolly the sheep 30 years on; and space rovers and the solar eclipse with the astronomer Megan Argo. Like this podcast? Please help us by supporting the Naked Scientists

The US are out of the World Cup after defeat by Belgium - even though one of their star players was on the pitch after his automatic one-match ban for a red card was suspended. President Trump admitted he'd intervened. Also: BBC Eye finds evidence of torture and sexual violence at detention centres for Ukrainians in Russia and occupied Ukraine. The story of a 12-year-old pulled alive from the rubble following two earthquakes in Venezuela. The body of Iran's former supreme leader is paraded through the streets of Tehran. Millions turn out to pay their last respects. The weight-loss drug, Wegovy, is now available in pill form in Britain. And if you thought China was over-populated - think again.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk Photo: US fan with face painted in national colours in Portland, Oregon. Credit: IMAGN IMAGES via Reuters/Denny Medley.

As a marijuana grower for a startup South American based company, Jake did some questionable things. Like the time he smuggled 500 marijuana plants through customs! Get into the weeds with us, and hear all of Jake's exploits.   HERS Thank you, HERS!  forhers.com/SECRET for your personalized, affordable care that gets you. Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A/S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit forhers.com. HOMECHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life!  HomeChef.com/SECRET.  Must be an active subscriber to receive free dessert. MINT MOBILE Make the switch! MINTMOBILE.com/SECRET PICTURES See pictures of the pirate grow shipping container, Sofia, the baby plants and the full legal facility in South America! They are waiting for you on Threads, Facebook, Instagram and X.  Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See this week's sponsors and their offers at secretroompodcast.com/codes  FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page!  Just ask to join, all are welcome. :) YOUR SECRET  Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!  

You stopped the weightloss shot, and the cravings came roaring back. Maybe you're scared it means the shot was the only thing that ever worked for you. In this episode, Corinne breaks down what Ozempic, Wegovy, and the other GLP-1 shots are actually doing, what they're not doing, and why the food noise comes back, sometimes not until after you've hit your goal weight. You'll hear why this isn't a willpower problem, what the eating was always trying to tell you, and one thing you can start doing tonight to figure out the real reason you reach for food. Whether you're on the shot, off it, or scared to ever start, this one's for you.   Get my free PDF — The 30-Second Question That Quiets Food Noise: https://www.nobsweightloss.com/30second

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; The risks of using gray-market retatrutide before FDA approval [52:15]; Key takeaways [54:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

It's Episode 22 of Season 24. Enter the dark waters of the Cape Fear River as we present tales about diabolical distractions."Please, No Smoking" by Sam Conn Pantle (Story starts around 00:03:50)Produced by Jeff ClementCast: Eddie - James Solis, Casey - Dan Zappulla"The Extra Ones" by Don Tobin (Story starts around 00:19:35)Produced by Claudius MooreCast: Albert - Graham Rowat, Mrs. Holloway - Mary Murphy, Man - Peter Lewis"Debunked" by Quincy Lee (Story starts around 00:44:10)TRIGGER WARNING!Produced by Jesse CornettCast: Max - Erin Lillis, Pete - Jesse Cornett, Nathan - Atticus Jackson, Woman - Linsay Rousseau, Sarah - Nichole Goodnight"The Doll" by Joseph Yenkavitch (Story starts around 01:16:00)Produced by Phil MichalskiCast: Narrator - Tanja Milojevic, Mom - Sarah Ruth Thomas, Girl - Nichole Goodnight"The Early Bus" by Liam Rose Philipson (Story starts around 01:50:00)TRIGGER WARNING!Produced by Phil MichalskiCast: Narrator - Jeff Clement, Jake - Matthew Bradford, Carlos - Dan Zappulla, Daniel - Kyle Akers, Big Kid #1 - Atticus Jackson, Big Kid #2 - Elie Hirschman, Mister Critter - Mike DelGaudio, Driver - Peter LewisThis episode is sponsored by:Home Chef - Home Chef's meal kits are rated #1 in quality, convenience, value, taste, and recipe ease. Head to homechef.com/nosleep to get 50% off and free shipping for your first box plus free dessert for life!Betterhelp - This episode is sponsored by BetterHelp. Take a step towards a better you. Our listeners get 10% off their first month at betterhelp.com/nosleep.Weight Loss by Hims - Ready to reach your weight loss goals? Weight Loss by Hims and WegovyÆ. Get a personalized, affordable plan that gets you. Go to Hims.com/nosleep.Click here to learn more about The NoSleep Podcast teamClick here to learn more about Quincy Lee Executive Producer & Host: David CummingsMusical score composed by: Brandon Boone"The Early Bus" illustration courtesy of Kelly TurnbullThe NoSleep Podcast is Human-made for Human Minds. No generative AI is used in any aspect of work.Audio program ©2026 - Creative Reason Media - The copyrights for each story are held by the respective authors. No duplication or reproduction of this audio program is permitted without the written consent of Creative Reason Media. No part of this audio program may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems. All rights reserved.